Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 7 Feb 2018 |
| Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2018 AGM of Orion Corporation | 24 Jan 2018 |
| Orion to investigate possible sale of Orion Diagnostica | 23 Jan 2018 |
| Orion Corporation: Managers' transactions - Ylppö Jukka | 3 Jan 2018 |
| Orion Corporation: Managers' transactions - Westerlund Riikka | 27 Dec 2017 |